We are live on !
Find out more
Profund Advisors Portfolio holdings
AUM
$3.48B
Turnover
14.37%
1-Year Est. Return
66.96%
ProFund Advisors manages the ProFunds mutual funds, which include index funds across sectors, bonds, currencies and crypto, as well as leveraged and inverse funds. The ProFunds brand dates from 1997, and its affiliate ProShares began offering leveraged and inverse ETFs in 2006. The Bitcoin ProFund tracks bitcoin futures rather than holding bitcoin itself.
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+66.96%
3 Year Est. Return
+258.11%
5 Year Est. Return
+342.15%
10 Year Est. Return
+1,333.1%
AUM
$3.48B
AUM Growth
-$153M
(-4.2%)
Cap. Flow
-$155M
Cap. Flow % of AUM
Cap. Flow %
-4.44%
Top 10 Holdings %
Top 10 Hldgs %
41.36%
Holding
1,225
New
50
Increased
319
Reduced
729
Closed
126
Avg Time Held
6.2
years
Top 10 Avg Time Held
4.5
years
Top 20 Avg Time Held
5.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$37.8M |
| 2 |
Alumis Inc
ALMS
|
+$2.98M |
| 3 |
Collegium Pharmaceutical
COLL
|
+$1.65M |
| 4 |
Reddit
RDDT
|
+$1.57M |
| 5 |
Septerna Inc
SEPN
|
+$1.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$46.8M |
| 2 |
Broadcom
AVGO
|
+$15.2M |
| 3 |
Micron Technology
MU
|
+$13.3M |
| 4 |
Apple
AAPL
|
+$12.8M |
| 5 |
Advanced Micro Devices
AMD
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 54.2% |
| 2 | Healthcare | 10.88% |
| 3 | Communication Services | 8.15% |
| 4 | Consumer Discretionary | 7.38% |
| 5 | Industrials | 4.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
Roper Technologies
ROP
$46.2B
| $2.64M | 0.08% |
7,542
-829
| -10% | -$318K |
2013 Q2
53 quarters
|
|
152
TG Therapeutics
TGTX
$9.32B
| $2.58M | 0.07% |
46,230
+9,717
| +27% | +$526K |
2023 Q1
14 quarters
|
|
153
Old Dominion Freight Line
ODFL
$35.8B
| $2.57M | 0.07% |
14,770
-1,335
| -8% | -$273K |
2020 Q2
25 quarters
|
|
154
Iovance Biotherapeutics
IOVA
$3.86B
| $2.56M | 0.07% |
172,638
-31,576
| -15% | -$226K |
2023 Q1
14 quarters
|
|
155
HDFC Bank
HDB
$114B
| $2.52M | 0.07% |
112,910
-7,852
| -7% | -$187K |
2013 Q2
53 quarters
|
|
156
Ferrovial N.V. Ordinary Shares
FER
$40.7B
| $2.52M | 0.07% |
46,505
-3,073
| -6% | -$189K |
2025 Q4
3 quarters
|
|
157
Protagonist Therapeutics
PTGX
$9.26B
| $2.5M | 0.07% |
17,772
+1,654
| +10% | +$236K |
2023 Q1
14 quarters
|
|
158
Halozyme
HALO
$14.9B
| $2.5M | 0.07% |
22,633
+886
| +4% | +$85.6K |
2020 Q4
23 quarters
|
|
159
Paychex
PAYX
$40.2B
| $2.5M | 0.07% |
25,333
-2,481
| -9% | -$287K |
2013 Q2
53 quarters
|
|
160
Axon Enterprise
AXON
$34.6B
| $2.49M | 0.07% |
5,894
-474
| -7% | -$256K |
2023 Q4
11 quarters
|
|
161
Exelixis
EXEL
$17.8B
| $2.48M | 0.07% |
42,521
+11,267
| +36% | +$628K |
2017 Q3
36 quarters
|
|
162
Kinder Morgan
KMI
$75.4B
| $2.45M | 0.07% |
81,309
-22,127
| -21% | -$702K |
2013 Q2
53 quarters
|
|
163
DexCom
DXCM
$31.5B
| $2.44M | 0.07% |
28,294
-2,719
| -9% | -$226K |
2019 Q4
27 quarters
|
|
164
Krystal Biotech
KRYS
$9.7B
| $2.43M | 0.07% |
7,313
+1,543
| +27% | +$534K |
2023 Q1
14 quarters
|
|
165
Copart
CPRT
$28B
| $2.41M | 0.07% |
88,356
-10,161
| -10% | -$305K |
2013 Q2
53 quarters
|
|
166
Targa Resources
TRGP
$67.8B
| $2.41M | 0.07% |
8,898
-2,442
| -22% | -$684K |
2020 Q4
23 quarters
|
|
167
ICICI Bank
IBN
$106B
| $2.4M | 0.07% |
87,126
-5,230
| -6% | -$154K |
2013 Q2
53 quarters
|
|
168
Walt Disney
DIS
$192B
| $2.39M | 0.07% |
22,810
-3,074
| -12% | -$315K |
2013 Q2
53 quarters
|
|
169
Itaú Unibanco
ITUB
$79.7B
| $2.35M | 0.07% |
276,011
-14,919
| -5% | -$120K |
2013 Q2
53 quarters
|
|
170
Spyre Therapeutics
SYRE
$8.93B
| $2.35M | 0.07% |
26,406
+6,987
| +36% | +$672K |
2024 Q2
9 quarters
|
|
171
Vale
VALE
$48.6B
| $2.34M | 0.07% |
174,418
-12,098
| -6% | -$176K |
2013 Q2
53 quarters
|
|
172
Wells Fargo
WFC
$251B
| $2.34M | 0.07% |
29,204
+2,332
| +9% | +$202K |
2013 Q2
53 quarters
|
|
173
Thomson Reuters
TRI
$51.4B
| $2.34M | 0.07% |
24,019
-2,243
| -9% | -$222K |
2025 Q3
4 quarters
|
|
174
PTC Therapeutics
PTCT
$5.2B
| $2.32M | 0.07% |
35,877
+12,904
| +56% | +$940K |
2023 Q1
14 quarters
|
|
175
Incyte
INCY
$24.6B
| $2.32M | 0.07% |
19,152
+4,430
| +30% | +$541K |
2013 Q2
53 quarters
|
|
Similar funds
TC
Profund Advisors's Q3 2026 Portfolio in Review
As of Q3 2026, Profund Advisors held 1,225 positions worth $3.48B, down 4.2% from $3.64B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Profund Advisors withdrew a net $155M in Q3 2026, closing 126 positions and reducing 729 holdings. Its most notable exit was Electronic Arts, an estimated $5.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 54% of assets, down from 56% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Profund Advisors opened a new position in SpaceX worth $41.3M.
- Profund Advisors's largest Q3 2026 buy was SpaceX: 273,453 shares worth $41.3M.
- Profund Advisors added most to Alumis Inc in Q3 2026, an estimated $2.98M increase.
- Profund Advisors's biggest Q3 2026 reduction was NVIDIA, cutting an estimated $46.8M.
- Profund Advisors fully exited Electronic Arts in Q3 2026, selling an estimated $5.2M.
- Profund Advisors's ten largest holdings make up 41% of its $3.48B portfolio in Q3 2026.
- Profund Advisors opened 50 new positions and closed 126 in Q3 2026.
- Profund Advisors's portfolio value fell 4.2% quarter-over-quarter to $3.48B.
Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.